154 related articles for article (PubMed ID: 22486586)
21. Endogenous inhibitors (GALFs) of 11beta-hydroxysteroid dehydrogenase isoforms 1 and 2: derivatives of adrenally produced corticosterone and cortisol.
Morris DJ; Latif SA; Hardy MP; Brem AS
J Steroid Biochem Mol Biol; 2007 May; 104(3-5):161-8. PubMed ID: 17459698
[TBL] [Abstract][Full Text] [Related]
22. Type 2 diabetes and metabolic syndrome are associated with increased expression of 11beta-hydroxysteroid dehydrogenase 1 in obese subjects.
Alberti L; Girola A; Gilardini L; Conti A; Cattaldo S; Micheletto G; Invitti C
Int J Obes (Lond); 2007 Dec; 31(12):1826-31. PubMed ID: 17593901
[TBL] [Abstract][Full Text] [Related]
23. Pharmacological characterization of the selective 11β-hydroxysteroid dehydrogenase 1 inhibitor, BI 135585, a clinical candidate for the treatment of type 2 diabetes.
Hamilton BS; Himmelsbach F; Nar H; Schuler-Metz A; Krosky P; Guo J; Guo R; Meng S; Zhao Y; Lala DS; Zhuang L; Claremon DA; McGeehan GM
Eur J Pharmacol; 2015 Jan; 746():50-5. PubMed ID: 25445047
[TBL] [Abstract][Full Text] [Related]
24. The role of 11beta-hydroxysteroid dehydrogenase in metabolic disease and therapeutic potential of 11beta-hsd1 inhibitors.
Saiah E
Curr Med Chem; 2008; 15(7):642-9. PubMed ID: 18336279
[TBL] [Abstract][Full Text] [Related]
25. Identification of novel 11β-HSD1 inhibitors by combined ligand- and structure-based virtual screening.
Lagos CF; Vecchiola A; Allende F; Fuentes CA; Tichauer JE; Valdivia C; Solari S; Campino C; Tapia-Castillo A; Baudrand R; Villarroel P; Cifuentes M; Owen GI; Carvajal CA; Fardella CE
Mol Cell Endocrinol; 2014 Mar; 384(1-2):71-82. PubMed ID: 24447464
[TBL] [Abstract][Full Text] [Related]
26. Increased whole-body and sustained liver cortisol regeneration by 11beta-hydroxysteroid dehydrogenase type 1 in obese men with type 2 diabetes provides a target for enzyme inhibition.
Stimson RH; Andrew R; McAvoy NC; Tripathi D; Hayes PC; Walker BR
Diabetes; 2011 Mar; 60(3):720-5. PubMed ID: 21266326
[TBL] [Abstract][Full Text] [Related]
27. In vivo activity of 11β-hydroxysteroid dehydrogenase type 1 in man: effects of prednisolone and chenodesoxycholic acid.
Diederich S; Quinkler M; Mai K; Schöneshöfer M; Baehr V; Pfeiffer A; Oelkers W; Eigendorff E
Horm Metab Res; 2011 Jan; 43(1):66-71. PubMed ID: 20925019
[TBL] [Abstract][Full Text] [Related]
28. Time of the day for 11beta-HSD1 inhibition plays a role in improving glucose homeostasis in DIO mice.
Véniant MM; Hale C; Komorowski R; Chen MM; St Jean DJ; Fotsch C; Wang M
Diabetes Obes Metab; 2009 Feb; 11(2):109-17. PubMed ID: 18479468
[TBL] [Abstract][Full Text] [Related]
29. 2-amino-1,3-thiazol-4(5H)-ones as potent and selective 11beta-hydroxysteroid dehydrogenase type 1 inhibitors: enzyme-ligand co-crystal structure and demonstration of pharmacodynamic effects in C57Bl/6 mice.
Johansson L; Fotsch C; Bartberger MD; Castro VM; Chen M; Emery M; Gustafsson S; Hale C; Hickman D; Homan E; Jordan SR; Komorowski R; Li A; McRae K; Moniz G; Matsumoto G; Orihuela C; Palm G; Veniant M; Wang M; Williams M; Zhang J
J Med Chem; 2008 May; 51(10):2933-43. PubMed ID: 18419108
[TBL] [Abstract][Full Text] [Related]
30. 11Beta-hydroxysteroid dehydrogenase type 1 and its role in the hypothalamus-pituitary-adrenal axis, metabolic syndrome, and inflammation.
Cooper MS; Stewart PM
J Clin Endocrinol Metab; 2009 Dec; 94(12):4645-54. PubMed ID: 19837912
[TBL] [Abstract][Full Text] [Related]
31. Medicinal chemistry of inhibitors of 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1).
Scott JS; Goldberg FW; Turnbull AV
J Med Chem; 2014 Jun; 57(11):4466-86. PubMed ID: 24294985
[TBL] [Abstract][Full Text] [Related]
32. Is the metabolic syndrome an intracellular Cushing state? Effects of multiple humoral factors on the transcriptional activity of the hepatic glucocorticoid-activating enzyme (11beta-hydroxysteroid dehydrogenase type 1) gene.
Iwasaki Y; Takayasu S; Nishiyama M; Tsugita M; Taguchi T; Asai M; Yoshida M; Kambayashi M; Hashimoto K
Mol Cell Endocrinol; 2008 Mar; 285(1-2):10-8. PubMed ID: 18313835
[TBL] [Abstract][Full Text] [Related]
33. Targeting the pre-receptor metabolism of cortisol as a novel therapy in obesity and diabetes.
Gathercole LL; Stewart PM
J Steroid Biochem Mol Biol; 2010 Oct; 122(1-3):21-7. PubMed ID: 20347978
[TBL] [Abstract][Full Text] [Related]
34. Carbenoxolone treatment attenuates symptoms of metabolic syndrome and atherogenesis in obese, hyperlipidemic mice.
Nuotio-Antar AM; Hachey DL; Hasty AH
Am J Physiol Endocrinol Metab; 2007 Dec; 293(6):E1517-28. PubMed ID: 17878220
[TBL] [Abstract][Full Text] [Related]
35. A novel highly potent and selective 11β-hydroxysteroid dehydrogenase type 1 inhibitor, UI-1499.
Byun SY; Shin YJ; Nam KY; Hong SP; Ahn SK
Life Sci; 2015 Jan; 120():1-7. PubMed ID: 25447448
[TBL] [Abstract][Full Text] [Related]
36. HIS-388, a novel orally active and long-acting 11β-hydroxysteroid dehydrogenase type 1 inhibitor, ameliorates insulin sensitivity and glucose intolerance in diet-induced obesity and nongenetic type 2 diabetic murine models.
Okazaki S; Takahashi T; Iwamura T; Nakaki J; Sekiya Y; Yagi M; Kumagai H; Sato M; Sakami S; Nitta A; Kawai K; Kainoh M
J Pharmacol Exp Ther; 2014 Oct; 351(1):181-9. PubMed ID: 25100752
[TBL] [Abstract][Full Text] [Related]
37. Comparative enzymology of 11beta-hydroxysteroid dehydrogenase type 1 from six species.
Arampatzis S; Kadereit B; Schuster D; Balazs Z; Schweizer RA; Frey FJ; Langer T; Odermatt A
J Mol Endocrinol; 2005 Aug; 35(1):89-101. PubMed ID: 16087724
[TBL] [Abstract][Full Text] [Related]
38. 11beta-hydroxysteroid dehydrogenase type 1 inhibitors for the treatment of type 2 diabetes.
Morgan SA; Tomlinson JW
Expert Opin Investig Drugs; 2010 Sep; 19(9):1067-76. PubMed ID: 20707593
[TBL] [Abstract][Full Text] [Related]
39. Inhibitors of 11beta-hydroxysteroid dehydrogenase type 1 for the treatment of metabolic syndrome.
Wang M
Curr Opin Investig Drugs; 2006 Apr; 7(4):319-23. PubMed ID: 16625818
[TBL] [Abstract][Full Text] [Related]
40. Upregulation of adipose 11-beta-hydroxysteroid dehydrogenase type 1 expression in ovariectomized rats is due to obesity rather than lack of estrogen.
Paulsen SK; Nielsen MP; Richelsen B; Bruun JM; Flyvbjerg A; Pedersen SB
Obesity (Silver Spring); 2008 Apr; 16(4):731-5. PubMed ID: 18379559
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]